AbbVie narrows assistance for 2022

Shares of AbbVie Inc.
ABBV,
+.65%
fell 2.9% in premarket trading on Friday immediately after the enterprise trimmed steerage for modified earnings for each share for the yr. AbbVie had earnings of $3.9 billion, or $2.21 per share, in the 3rd quarter of 2022, in comparison with $3.2 billion, or $1.78 per share, in the same quarter a calendar year back. Modified earnings for every share were $3.66, against a FactSet of $3.57. The corporation reported revenue of $14.8 billion for the quarter, up from $14.2 billion in the same 3 months of very last yr. The FactSet consensus was $14.9 billion. Humira generated $5.5 billion in earnings for the quarter, against a FactSet consensus of $5.6 billion. AbbVie narrowed its steerage for modified EPS for the calendar year, stating it now expects $13.84 to $13.88 for each share. The prior advice was $13.76 to $13.96 per share. AbbVie’s inventory is up 13.3% this calendar year, even though the broader S&P 500
SPX,
-.61%
is down 19.6%.